UBS Adjusts McKesson Price Target to $1,200 From $1,080, Maintains Buy Rating
UBS raised its price target for McKesson to $1,200 from $1,080 while maintaining a buy rating. The stock is currently trading at $1,003.26, up 0.46% on the day and 7.35% over the past year. Baird also recently adjusted its price target for McKesson to $1,017 from $1,015.
How this was made
The 30-second read
Why it matters
The upgrade could attract buying interest, especially from investors tracking analyst recommendations.
Market read
Analyst target changes are a common catalyst for short‑term price movement in large-cap stocks.
What to watch
No new operational or financial data accompanies the target change.
Background
UBS adjusted its valuation model for McKesson, increasing the price target by $120.
Ticker impact
UBS raised its price target for McKesson to $1,200 from $1,080, indicating a more optimistic outlook.
potential upside as the market prices in the higher target
Target raise reflects improved valuation expectations; no new corporate event, but analysts' views can move the stock.
Market effects
Higher target may signal optimism for the healthcare distribution sector.
U.S. healthcare stocks could see modest support.
Limited to U.S. markets.
Counterpoint
Target raise may be premature if underlying earnings growth does not meet expectations.
Key entities
- analystUBS
Equity research firm that issued the target raise.
- companyMcKesson
U.S. healthcare services and distribution company.
